🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

    Bayer AG

    "Patients with interstitial lung disease associated pulmonary hypertension"

    phase 2 other active

    1 trial

  2. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 2 mab completed

    1 trial

  3. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Ichthyosis

    phase 2 small molecule terminated

    1 trial

  4. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acneiform Eruptions

    phase 2 mab terminated

    1 trial

  5. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Acne Vulgaris

    phase 2 small molecule completed

    1 trial

  6. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Hidradenitis Suppurativa

    phase 2 mab completed

    1 trial

  7. Imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Palmoplantar Pustulosis

    phase 2 mab completed

    1 trial

  8. Imx-110

    Immix Biopharma

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  9. Inaxaplin

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial

  10. Inhixa 4,000 IU (40 mg)/0.4 mL solution for injection in pre-filled syringe, CLEXANE 4 000 UI (40 mg)/0,4 ml solution injectable en seringue préremplie, REGN7508

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  11. Injection of humanized nerve growth factor (NGF) antibody

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Cancer Pain

    phase 2 small molecule active

    1 trial

  12. Inlyta 1 mg film-coated tablets, Inlyta 3 mg film-coated tablets, CELLTOP 50 mg, capsule molle, ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion

    ISTA Pharma Limited

    Ependymoma, Medulloblastoma

    phase 2 small molecule active

    1 trial

  13. Investigational new drug company code: BGS649

    Mereo BioPharma Group plc

    Obese Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  14. Iomab-B

    Actinium Pharmaceuticals

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. Iptacopan

    Novartis Pharmaceuticals

    Immune Thrombocytopenia (ITP)

    phase 2 small molecule terminated

    1 trial

  16. Isis 420915/GSK 299872

    IONIS PHARMACEUTICALS INC

    Amyloidosis

    phase 2 small molecule terminated

    1 trial

  17. Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy

    Eledon Pharmaceuticals

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  18. Itacitinib

    Pari Pharma GmbH

    Adults patients having non severe HLH

    phase 2 small molecule active

    1 trial

  19. Itacitinib, placebo of itacitinib 100mg

    Pari Pharma GmbH

    Patients with newly or active diffuse Systemic sclerosis (SSc) at the time of screening

    phase 2 small molecule active

    1 trial

  20. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  21. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  22. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  23. JAB-21822

    Lacuna Pharma Pty Ltd

    advanced solid tumors with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  24. JBT-101

    Corbus Pharmaceuticals Holdings

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources